ZUMA-7: CAR T-cell therapy in earlier lines of therapy benefits patients with relapsed/refractory large B-cell lymphoma

Autologous anti CD19 chimeric antigen receptor (CAR) T-cell therapy is approved for patients with relapsed/refractory large B-cell lymphoma after ≥2 prior systemic therapies. But according to the results from the global ZUMA-7 study, patients benefit significantly when administered in earlier lines of therapy.